Destiny Pharma’s Joe Eagle to step down from Board

pharmafile | September 23, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs to address the global crisis caused by antimicrobial resistance (AMR), has announced that after 18 years on the board, Joe Eagle is to step down with immediate effect.

Eagle has been instrumental in the financing and strategic direction of Destiny as a private company and brought his expertise for its lead candidate, XF-73 for the prevention of post-surgical infections. A search for a replacement is underway.

Nick Rodgers, Chairman of Destiny Pharma, said: “I would like to thank Joe for his considerable contribution to the Company throughout the development as a private company and the transition onto the AIM market.

“Joe’s understanding of the pharma market and company development has been of great value to Destiny and I am sorry to see him go. We wish him all the very best for the future.”

Joe Eagle himself commented: “I continue to believe that Destiny Pharma, through its XF platform, will develop unique and life-saving antimicrobials to counter the worldwide threat of antimicrobial resistance.

“I have seen the development of the Company from a small private enterprise to a successful, asset rich public company and wish all the members of the company every success with their future endeavours. It has been a privilege to work with you all.”

Currently Destiny Pharma is undergoing a phase 2b clinical trial with its XF candidates designed to tackle antibiotic-resistant bacteria, often known as ‘superbugs’.

Related Content

No items found

Latest content